Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's diseases linked to protein misfolding. The company boasts a robust pipeline supported by proprietary technologies aimed at addressing substantial unmet medical needs within this urgent therapeutic space. Through strategic partnerships and a strong commitment to research and development, Sionna is well-positioned to become a leader in the biopharmaceutical sector, dedicated to enhancing patient outcomes and overall quality of life with its groundbreaking neurological treatments.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-108.84M |
| Operating Margin | 0.00% |
| Return on Equity | -32.30% |
| Return on Assets | -21.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.88 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $45.15M |
| Float | $20.47M |
| % Insiders | 7.88% |
| % Institutions | 99.59% |
Volatility is currently contracting
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SION and any ticker you trade — then tracks every position and per-strategy win rate.
